Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
doi: https://doi.org/10.1101/2021.01.05.21249310
Ravikirti
1Department of General Medicine, All India Institute of Medical Sciences (AIIMS), Patna, India
Roles: Additional Professor and Head
Ranjini Roy
2Department of General Medicine, AIIMS, Patna, India
Roles: Postgraduate Trainee
Chandrima Pattadar
2Department of General Medicine, AIIMS, Patna, India
Roles: Postgraduate Trainee
Rishav Raj
3Department of General Medicine, AIIMS, Patna
Roles: Postgraduate Trainee
Neeraj Agarwal
4Department of Community and Family Medicine, AIIMS, Bibi Nagar, India
Roles: Professor and Head
Bijit Biswas
5Department of Community and Family Medicine, AIIMS, Patna, India
Roles: Senior Resident
Pramod Kumar Majhi
6Department of Pharmacology, AIIMS, Patna, India
Roles: Assistant Professor and Head
Deependra Kumar Rai
7Department of Pulmonary Medicine, AIIMS, Patna, India
Roles: Additional Professor and Head
Shyama
3Department of General Medicine, AIIMS, Patna
Roles: Assistant Professor
Anjani Kumar
3Department of General Medicine, AIIMS, Patna
Roles: Assistant Professor
Asim Sarfaraz
9Department of Microbiology, AIIMS, Patna
Roles: Assistant Professor
Data Availability
The data can be made available by the corresponding author on rasonable request.
Posted January 09, 2021.
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
medRxiv 2021.01.05.21249310; doi: https://doi.org/10.1101/2021.01.05.21249310
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
medRxiv 2021.01.05.21249310; doi: https://doi.org/10.1101/2021.01.05.21249310
Subject Area
Subject Areas
- Addiction Medicine (354)
- Allergy and Immunology (678)
- Anesthesia (182)
- Cardiovascular Medicine (2678)
- Dermatology (227)
- Emergency Medicine (404)
- Epidemiology (12310)
- Forensic Medicine (10)
- Gastroenterology (769)
- Genetic and Genomic Medicine (4156)
- Geriatric Medicine (390)
- Health Economics (685)
- Health Informatics (2693)
- Health Policy (1010)
- Hematology (365)
- HIV/AIDS (861)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (444)
- Neurology (3931)
- Nursing (212)
- Nutrition (584)
- Oncology (2070)
- Ophthalmology (595)
- Orthopedics (243)
- Otolaryngology (307)
- Pain Medicine (253)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1130)
- Primary Care Research (461)
- Public and Global Health (6577)
- Radiology and Imaging (1420)
- Respiratory Medicine (876)
- Rheumatology (414)
- Sports Medicine (345)
- Surgery (455)
- Toxicology (54)
- Transplantation (189)
- Urology (169)